In The News
Albanese government dumps misinformation bill
Katy Perry wins appeal in trade mark fight with Aussie designer
Lawyers in NSW can’t use AI to generate affidavits, witness statements, court says
Group members get nothing in RoundUp class action settlement
Second judge has rosier view of claims in class action over $85M development
Pharmacor says AstraZeneca’s Brilinta patent should not have been extended
Law firm report clears WiseTech founder Richard White of misconduct
Union boss says she faces charges over alleged $2.7M scheme, wants FWC case stayed
US has immunity from Darwin-based soldier’s personal injury suit: court
Clyde & Co sued by insurers over indemnity advice
Please login to bookmarkClose

A former QRx Pharma director’s prediction that shareholders would not receive “anything of consequence” from a class action settlement has proven true, with only a small slice of the $7 million settlement expected to go to shareholders.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au